{"id":5755,"date":"2026-10-28T09:54:15","date_gmt":"2026-10-28T08:54:15","guid":{"rendered":"https:\/\/www.access2meds.eu\/?page_id=5755"},"modified":"2026-10-28T09:54:20","modified_gmt":"2026-10-28T08:54:20","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/fr\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; admin_label=\u00a0\u00bbHeader\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bb2e264158-b54d-4d7f-8146-8c8b7ca64cef\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/header-Publications.jpeg\u00a0\u00bb background_position=\u00a0\u00bbtop_center\u00a0\u00bb background_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb background_image_phone=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Mobile-Header-6.png\u00a0\u00bb background_enable_image_phone=\u00a0\u00bbon\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_padding=\u00a0\u00bb7px|30px||30px|false|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_font=\u00a0\u00bb|700||on|||||\u00a0\u00bb header_font_size=\u00a0\u00bb80px\u00a0\u00bb custom_margin=\u00a0\u00bb11px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h1><span style=\"color: #e95f6c;\">Results<\/span><\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#e1e2ed\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb||37px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>EXPLORE ASCERTAIN\u2019S RESEARCH FINDINGS, TOOLS, AND POLICY OUTPUT<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>This page provides access to the results of the ASCERTAIN project. In line with our commitment to transparency and open science, all project outcomes will be made publicly available here as they are developed.<\/p>\n<h5>Our results will include:<\/h5>\n<ul>\n<li>Key findings from the project\u2019s research activities<\/li>\n<li>Tools and resources developed within ASCERTAIN<\/li>\n<li>Policy recommendations and position papers<\/li>\n<li>Materials from stakeholder engagement activities<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bbRGBA(255,255,255,0)\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb||37px||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>PUBLICATIONS<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.7&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li><a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2715977?trk=organization_guest_main-feed-card_feed-article-content#d1e634\">Kal\u00f3, Z., Rutten-van M\u00f6lken, M., Aas, E., Salcher-Konrad, M., Tesa\u0159, T., Belleman, T., et al. (2026). Principles of selecting cost-effectiveness thresholds in price-taker countries. Expert Review of Pharmacoeconomics &amp; Outcomes Research. Advance online publication.<\/a> https:\/\/doi.org\/10.1080\/14737167.2026.2715977<\/li>\n<li><a href=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/06\/Wu-et-al_s41669-026-00656-9_final.pdf\">Wu, Y. S., Burger, E. A., Holmboe, F., Bangum, M., Oteiza, F., Bugge, C., S\u00e6ther, E. M., &amp; Aas, E. (2026). <em data-start=\"175\" data-end=\"355\">Integrating structured expert elicitation with external evidence to inform earlier reimbursement decisions: A Norwegian case study of selpercatinib for non-small cell lung cancer<\/em>. <em data-start=\"357\" data-end=\"383\">PharmacoEconomics \u2013 Open<\/em>. Advance online publication. https:\/\/doi.org\/10.1007\/s41669-026-00656-9<\/a><\/li>\n<li><a href=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/06\/Applications-of-Structural-Expert-Elicitations-for-Economic-Evaluations_-A-Systematic-Review-Update.pdf\">Geisler, B. P., Holmboe, F., Starinieri, I., &amp; Aas, E. (2026). <em data-start=\"129\" data-end=\"230\">Applications of structural expert elicitations for economic evaluations: A systematic review update<\/em>. <strong data-start=\"232\" data-end=\"253\">Pharmacoeconomics<\/strong>. Advance online publication. https:\/\/doi.org\/10.1007\/s40273-026-01628-x<\/a><\/li>\n<li><a href=\"https:\/\/www.cambridge.org\/core\/journals\/health-economics-policy-and-law\/article\/legal-implications-of-joint-clinical-assessments-under-the-eu-hta-regulation\/A2C8BEE677F3566E63EFBCE07557AD16\">Xander NSH, Rutten-van M\u00f6lken MPMH, Bertin L, Miljkovi\u0107 N, Uyl-de Groot CA. Legal implications of joint clinical assessments under the EU HTA regulation. Health Economics, Policy and Law. Published online 2026:1-13. doi:10.1017\/S1744133126100413<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1007\/s10198-025-01834-y\">Xander, N.S.H., Belleman, T., Salcher-Konrad, M. et al. Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review. Eur J Health Econ (2025). https:\/\/doi.org\/10.1007\/s10198-025-01834-y<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1016\/j.jmoldx.2025.06.006\">Henkel, P. S., Aas, E., Russnes, H. G., Dyvik, I., Fagereng, G. L., Helland, \u00c5., R\u00f8genes, H., Lien, T. G., &amp; Pedersen, K. (2025). <em data-start=\"265\" data-end=\"419\">Microcosting Study of Genomic Profiling for Precision Cancer Medicine: Application from the National Infrastructure for Precision Diagnostics in Norway.<\/em> <em data-start=\"420\" data-end=\"459\">The Journal of Molecular Diagnostics.<\/em> Advance online publication, July 22, 2025. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.06.006<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1016\/j.jval.2024.06.003\">Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot, Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands, Value in Health, 2024,<\/a><br \/><a href=\"https:\/\/doi.org\/10.1016\/j.jval.2024.06.003\">https:\/\/doi.org\/10.1016\/j.jval.2024.06.003<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1371\/journal.pone.0293264\">Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, et al. (2024) Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLOS ONE 19(2): e0293264. https:\/\/doi.org\/10.1371\/journal.pone.0293264<\/a><\/li>\n<li><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211883726000031?via%3Dihub\">Uyl-de Groot, C. A., Xander, N.S.H., Belleman, T., Burger, E. A., Doeswijk, R., Durand-Zaleski, I., Geisler, B. P., Groene, O., Hendrickx, A., Henkel, P. S., Heine, R., Hui\u0107, M., Melli, M., Morgan, K., Racovi\u021ba, M., Quinonez, G., Rutten-van M\u00f6lken, M. P. M. H., Tesa\u0159, T., Thielen, F. W., Schneider, P., Wu, Y. S., Salcher-Konrad, M., &amp; Aas, E. (2026). Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN project. Health Policy and Technology, 15(2), 101155.<\/a><\/li>\n<li><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211883726000031?via%3Dihub\"><\/a><a href=\"https:\/\/osf.io\/udsg4\/files\/n6sm7\">Salcher-Konrad, M., Schneider, P., Zimmermann, N., &amp; Hendrickx, A. (2025). Scoping review of definitions for fair prices of new health technologies (pre-print). OSF. https:\/\/osf.io\/udsg4<\/a><\/li>\n<li><a href=\"https:\/\/link.springer.com\/chapter\/10.1007\/978-3-662-72460-6_11\">Uyl-de Groot CA, Xander NS, Hendrickx A, Salcher-Konrad M. Auf dem Weg zu einer gerechten und nachhaltigen Preisgestaltung im Gesundheitswesen: Fokus auf das AIM-Fair-Price-Modell und das ASCERTAIN-Projekt [Toward Equitable and Sustainable Medicine Pricing: Focus on the AIM Fair Price Model. and the ASCERTAIN project]. In: Schr\u00f6der H, Th\u00fcrmann PA, Thiede M, Enners S, Busse R (Eds.): Arzneimittel-Kompass 2025. Die Preisfrage: Wege zu fairen L\u00f6sungen [Medicines compass 2025. The question about the price. Approaches for fair solutions]. Springer, Berlin, 2025, p. 153-64<\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>POSITION PAPERS<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/ASCERTAIN_position_paper_wp4.pdf\">PRICING METHODS FOR INNOVATIVE HEALTH TECHNOLOGIES<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/ASCERTAIN_position_paper_wp5.pdf\">COST-EFFECTIVENESS AND BUDGET IMPACT MODELS FOR INNOVATIVE HEALTH TECHNOLOGIES (IHT)<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/ASCERTAIN_position_paper_wp6.pdf\">REIMBURSEMENT FOR INNOVATIVE HEALTH TECHNOLOGIES<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>LEAFLET<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/leaflet\/price_regulation.pdf\">Leaflet on price regulation for medicines.<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/leaflet\/qaly.pdf\">Leaflet on QALY.<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/leaflet\/uncertain_data.pdf\">Leaflet on uncertain data.<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/leaflet\/regulatory_diagnostics.pdf\">Leaflet on regulatory diagnostics.<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.8&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/leaflet\/global_cost-effectiveness_models.pdf\">Leaflet on cost-effectiveness models.<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>BROCHURE<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/brochure.pdf\">Cliquez ici pour lire la brochure du projet<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>VID\u00c9O<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li><a href=\"https:\/\/youtu.be\/sbPnTmX8Uxs?si=azJ_n-qw8NEKwge6\">Kick-off Meeting\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/fvjJ4-2nOxk?si=lzdTWPg1PYdBNCzN\">Animated explainer video\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/JjYDG7BDNDE\">Behind the Scenes: Making the &lsquo;3 Things About&rsquo; Series<\/a><a href=\"https:\/\/youtu.be\/JWVUuhTT8Fo\"><\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/8NhuaohK_Qg\">3 Things About Market Access<\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/OlmiWOpy6IA\">3 Things About Tiered Pricing <\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/6ZtwscRvEls\">3 Things About Pricing of New Drugs<\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/e36OtJA90Qg\">3 Things About Reimbursement <\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/xMF2ddO9abM\">3 Things About Cost-Effectiveness<\/a><\/li>\n<li><a href=\"https:\/\/youtu.be\/JWVUuhTT8Fo\">3 Things About Value of New Cancer Drugs<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=TIgtrEo8C14\">What is reference pricing?<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=0jAH1R8pwo0\">What is a list price for a medicine?<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=ASqKEV-92vI\">What is a fair price?<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=TyL_2O6uTSg\">How do the views or perspectives of patients influence decisions on medicine access?<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=E0ZmPm-ph48\">What is a framework?<\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=kUKLk_xeTTg\">The Journey of a Medicine<\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>ACCESS2MEDS FRAMEWORK<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/access2meds_framework_V3.pdf\">ACCESS2MEDS FRAMEWORK V3<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>LETTRE D&rsquo;INFORMATION<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-1\/\">Newsletter 01 &#8211; September 2023<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-2\/\">Newsletter 02 &#8211; March 2024<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-3\/\">Newsletter 03 &#8211; September 2024<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-4\/\">Newsletter 04 &#8211; March 2025<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-5\/\">Newsletter 05 &#8211; October 2025<\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/ascertain-newsletter-6\/\"><strong>Newsletter 06 &#8211; April 2026<\/strong><\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=\u00a0\u00bboff|off|off\u00a0\u00bb module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>POSTER<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.5&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li>Geisler, B.P., Meltzer, S., Burger, E.A., Aas, E., Ree, A.H. Value of immune checkpoint blockade (ICB) in microsatellite stable\/mismatch repair proficient (MSS\/pMMR) metastatic colorectal cancer (mCRC). Annals of Oncology. 2024;35:S936\u2013S937.<br \/>DOI: <a href=\"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.159\">https:\/\/doi.org\/10.1016\/j.annonc.2024.08.159<\/a><\/li>\n<li>Geisler, B.P., Meltzer, S., Burger, E.A., Ree, A.H., Aas, E. Cost-effectiveness of Next Generation Sequencing to Select Microsatellite Stable\/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy. Abstract forthcoming in a Value in Health Supplement<\/li>\n<li>Salcher-Konrad, M. Pharmacoeconomic perspective on medicines prices and efficiency in health systems. pharmakon 2025.<\/li>\n<li>Salcher-Konrad, M. What is a fair price? Reviewing \u201cfair pricing\u201d definitions from different perspectives. EHA 2024 Congress.<\/li>\n<li>Salcher-Konrad, M., Hendrickx, A., Schneider, P., Zimmermann, N. Defining fair prices for new health technologies. 5th PPRI Conference 2024: Ensuring access to affordable medicines through innovative policies, Vienna, 25\u201326 April 2024.<\/li>\n<li>Salcher-Konrad, M., Zimmermann, N., Schneider, P., Hendrickx, A. What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies. ISPOR Europe 2023, Copenhagen, 14 November 2023.<\/li>\n<li>Salcher-Konrad, M., et al. \u00ab\u00a0Fair\u00a0\u00bb or \u00ab\u00a0optimal\u00a0\u00bb pricing of medicines: how do definitions for fair pricing align with economic theory? EuHEA 2024.<\/li>\n<li>Xander, et al. Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products. ISPOR Europe 2025<\/li>\n<li>Xander, et al. Determining and Applying Fair Prices of Innovative Health Technologies: A Stakeholder View Analysis. lolaHESG 2025.<\/li>\n<li>Xander, et al. Price Determinants and Pricing Policies Concerning Potentially Innovative Health Technologies: A Scoping Review. ISPOR Europe 2024<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>WEBINARS<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li>How Can Precision Medicine, Genetic Testing, and Biomarkers Support Better Healthcare Decisions? &#8211; June 2026<br \/><span class=\"cf0\"><\/span><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=aXXoDoQD5q8&amp;embeds_referring_euri=https%3A%2F%2Fwww.mpeurope.org%2F&amp;embeds_referring_origin=https%3A%2F%2Fwww.mpeurope.org&amp;source_ve_path=OTY3MTQ\"><span class=\"cf0\">How<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">are<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">costs<\/span><span class=\"cf0\"> and <\/span><span class=\"cf0\">medicine<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">effectiveness<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">part<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">of<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">decision-making<\/span><span class=\"cf0\"> in <\/span><span class=\"cf0\">medicine<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">access<\/span><span class=\"cf0\">? &#8211;\u00a0 <\/span><span class=\"cf0\">October<\/span><span class=\"cf0\"> 2025<\/span><\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=b5Al1jSKu70&amp;list=PLuQPQ3pwGl5v1LDlYQhC0VS_It7fnv1tI\"><span class=\"cf0\">How<\/span><span class=\"cf0\"> do different countries <\/span><span class=\"cf0\">make<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">decisions<\/span><span class=\"cf0\"> on <\/span><span class=\"cf0\">reimbursing<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">new<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">medicines<\/span><span class=\"cf0\">? &#8211; April 2025<\/span><\/a><\/li>\n<li><a href=\"https:\/\/www.youtube.com\/watch?v=ew3l6nYjW6Y\"><span class=\"cf0\">Basics <\/span><span class=\"cf0\">of<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">medicines<\/span><span class=\"cf0\"> pricing in Europe &#8211; March 2024<\/span><\/a><\/li>\n<li><a href=\"https:\/\/www.access2meds.eu\/european-public-health-week-gog-colloquium-greener-pharmaceuticals-policies-for-an-environmentally-sustainable-pharmaceutical-system\/\"><span class=\"cf0\">Greener<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">pharmaceuticals<\/span><span class=\"cf0\">: <\/span><span class=\"cf0\">policies<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">for<\/span><span class=\"cf0\"> an <\/span><span class=\"cf0\">environmentally<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">sustainable<\/span><span class=\"cf0\"> <\/span><span class=\"cf0\">pharmaceutical<\/span><span class=\"cf0\"> system<\/span><\/a><\/li>\n<\/ul>\n<p><!--EndFragment --><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.25.1&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>Communiqu\u00e9s de presse<\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.6&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/ASCERTAIN-Press-Release-01.pdf\">Press Release 01<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/09\/ASCERTAIN-Press-Release-02.pdf\">Press Release 02<\/a><\/strong><\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/08\/ASCERTAIN-Press-Release-03.pdf\"><strong>Press Release 03<\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.access2meds.eu\/ASCERTAIN%20Press%20Release%2004.pdf\"><strong>Press Release 04<\/strong><\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row module_class=\u00a0\u00bbrowmitklapptext\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_2_font=\u00a0\u00bb|600||on|||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h2>AUTRES  <\/h2>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li><a href=\"https:\/\/www.access2meds.eu\/glossary.pdf\">Project glossary<\/a><\/li>\n<li>Interview for Dagens Medisin (news paper and trade magazine for Norwegian healthcare personnel and other employees within the healthcare sector): Camilla \u00d8. Ondrckova: \u201cNye, norske data kan f\u00f8re til ny behandling for avansert tykktarmskreft\u201d (in Norwegian) <a href=\"https:\/\/www.dagensmedisin.no\/esmo-esmo-2024-forskning\/nye-norske-data-kan-fore-til-ny-behandling-for-avansert-tykktarmskreft\/651327\">https:\/\/www.dagensmedisin.no\/esmo-esmo-2024-forskning\/nye-norske-data-kan-fore-til-ny-behandling-for-avansert-tykktarmskreft\/651327<\/a><\/li>\n<li>Interview for Health Talk (website and video channel): \u00abEr immunterapi mot tarmkreft kostnadseffektivt? Biomark\u00f8rer kan v\u00e6re n\u00f8kkelen\u00bb (in English): <a href=\"https:\/\/www.healthtalk.no\/tarmkreft\/er-immunterapi-mot-tarmkreft-kostnadseffektivt-biomarkorer-kan-vaere-nokkelen\/189801\">https:\/\/www.healthtalk.no\/tarmkreft\/er-immunterapi-mot-tarmkreft-kostnadseffektivt-biomarkorer-kan-vaere-nokkelen\/189801<\/a>\u00a0 (teaser)<\/li>\n<li>DM Arena Post ESMO (post-conference recap, organized by Dagens Medisin) <a href=\"https:\/\/www.dagensmedisin.no\/dmarena\/dm-arena-post-esmo-opptak-tilgjengelig-na\/646377\">https:\/\/www.dagensmedisin.no\/dmarena\/dm-arena-post-esmo-opptak-tilgjengelig-na\/646377<\/a><\/li>\n<li>Vumedi video, summary of the ESMO talk <a href=\"https:\/\/www.vumedi.com\/video\/esmo-2024-insights-the-value-of-immune-checkpoint-blockade-in-msspmmr-mcrc\/\">https:\/\/www.vumedi.com\/video\/esmo-2024-insights-the-value-of-immune-checkpoint-blockade-in-msspmmr-mcrc\/<\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00a0\u00bb1&Prime; module_id=\u00a0\u00bbcontact\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_color=\u00a0\u00bb#86B8BD\u00a0\u00bb custom_margin=\u00a0\u00bb||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb16px||75px||false|false\u00a0\u00bb box_shadow_style=\u00a0\u00bbpreset7&Prime; box_shadow_horizontal=\u00a0\u00bb0px\u00a0\u00bb box_shadow_vertical=\u00a0\u00bb-274px\u00a0\u00bb box_shadow_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_module=\u00a0\u00bb910&Prime; saved_tabs=\u00a0\u00bball\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb header_font=\u00a0\u00bbPoppins semibold|||on|||||\u00a0\u00bb header_font_size=\u00a0\u00bb36px\u00a0\u00bb custom_margin=\u00a0\u00bb14px||23px||false|false\u00a0\u00bb custom_margin_tablet=\u00a0\u00bb\u00a0\u00bb custom_margin_phone=\u00a0\u00bb||30px||false|false\u00a0\u00bb custom_margin_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb header_font_size_phone=\u00a0\u00bb24px\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<h1>Contact<\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_font=\u00a0\u00bbPoppins regular||||||||\u00a0\u00bb text_text_color=\u00a0\u00bb#393C84&Prime; text_font_size=\u00a0\u00bb24px\u00a0\u00bb text_line_height=\u00a0\u00bb1.33em\u00a0\u00bb module_alignment=\u00a0\u00bbright\u00a0\u00bb custom_margin=\u00a0\u00bb||0px||false|false\u00a0\u00bb text_font_size_tablet=\u00a0\u00bb\u00a0\u00bb text_font_size_phone=\u00a0\u00bb18px\u00a0\u00bb text_font_size_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>N&rsquo;h\u00e9sitez pas \u00e0 nous contacter si vous avez des questions ou des commentaires ! Nous vous r\u00e9pondrons dans les plus brefs d\u00e9lais. <\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00a0\u00bb1_3,1_3,1_3&Prime; use_custom_gutter=\u00a0\u00bbon\u00a0\u00bb module_class=\u00a0\u00bbtablet-three-cols\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb max_width_tablet=\u00a0\u00bb980px\u00a0\u00bb max_width_phone=\u00a0\u00bb500px\u00a0\u00bb max_width_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_padding=\u00a0\u00bb0px|30px|0px|30px|false|true\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbdisplay:flex;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbdisplay:flex; flex-direction:column;\u00a0\u00bb][et_pb_column type=\u00a0\u00bb1_3&Prime; _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|tablet\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbmargin-bottom:0;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbmargin-bottom:20px;\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png\u00a0\u00bb title_text=\u00a0\u00bbCarin_Uyl-de-Groot\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>Pour les questions relatives \u00e0 la recherche :<\/p>\n<p><strong>Carin Uyl-de Groot<\/strong><br \/>Coordinatrice de projet<\/p>\n<p>Universit\u00e9 Erasmus de Rotterdam<br \/><a href=\"mailto:uyl@eshpm.eur.nl\">uyl@eshpm.eur.nl<\/a><br \/>T\u00e9l\u00e9phone : +31 10 4081583<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_3&Prime; _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb background_color=\u00a0\u00bb#393C84&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb custom_css_main_element_last_edited=\u00a0\u00bbon|phone\u00a0\u00bb custom_css_main_element_tablet=\u00a0\u00bbmargin-bottom:0;\u00a0\u00bb custom_css_main_element_phone=\u00a0\u00bbmargin-bottom:20px;\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png\u00a0\u00bb title_text=\u00a0\u00bbMarcel-Langone\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>Pour des questions g\u00e9n\u00e9rales sur le projet :<\/p>\n<p><strong>Marcel Langone Marques<\/strong><br \/>Chef de projet<\/p>\n<p>Universit\u00e9 Erasmus de Rotterdam<br \/><a href=\"mailto:marcel.langonemarques@eur.nl\">marcel.langonemarques@eur.nl<\/a><br \/>T\u00e9l\u00e9phone : +31 10 4081583<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00a0\u00bb1_3&Prime; _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbbe0fba28-f74a-4ba0-9a8d-9cd30aca805d\u00a0\u00bb background_color=\u00a0\u00bb#048EA3&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_image src=\u00a0\u00bbhttps:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png\u00a0\u00bb title_text=\u00a0\u00bbMon projet-1 (7)\u00a0\u00bb _builder_version=\u00a0\u00bb4.21.0&Prime; _module_preset=\u00a0\u00bba348f9e0-d57b-4c22-b522-c52b784fe57f\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00a0\u00bb4.20.2&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb text_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb link_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p>Pour les communications :<\/p>\n<p><strong>Lena Jessen<\/strong><br \/>Chef de projet<\/p>\n<p>OptiMedis<br \/><a href=\"mailto:l.jessen@optimedis.de\">l.jessen@optimedis.de<\/a><br \/>T\u00e9l\u00e9phone : +49 40 226211490<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ResultsEXPLORE ASCERTAIN\u2019S RESEARCH FINDINGS, TOOLS, AND POLICY OUTPUTThis page provides access to the results of the ASCERTAIN project. In line with our commitment to transparency and open science, all project outcomes will be made publicly available here as they are developed. Our results will include: Key findings from the project\u2019s research activities Tools and resources developed within ASCERTAIN Policy recommendations and position papers Materials from stakeholder engagement activities &nbsp;PUBLICATIONS Kal\u00f3, Z., Rutten-van M\u00f6lken, M., Aas, E., Salcher-Konrad, M., Tesa\u0159, T., Belleman, T., et al. (2026). Principles of selecting cost-effectiveness thresholds in price-taker countries. Expert Review of Pharmacoeconomics &amp; Outcomes Research. Advance online publication. https:\/\/doi.org\/10.1080\/14737167.2026.2715977 Wu, Y. S., Burger, E. A., Holmboe, F., Bangum, M., Oteiza, F., Bugge, C., S\u00e6ther, E. M., &amp; Aas, E. (2026). Integrating structured expert elicitation with external evidence to inform earlier reimbursement decisions: A Norwegian case study of selpercatinib for non-small cell lung cancer. PharmacoEconomics \u2013 Open. Advance online publication. https:\/\/doi.org\/10.1007\/s41669-026-00656-9 Geisler, B. P., Holmboe, F., Starinieri, I., &amp; Aas, E. (2026). Applications of structural expert elicitations for economic evaluations: A systematic review update. Pharmacoeconomics. Advance online publication. https:\/\/doi.org\/10.1007\/s40273-026-01628-x Xander NSH, Rutten-van M\u00f6lken MPMH, Bertin L, Miljkovi\u0107 N, Uyl-de Groot CA. Legal implications of joint clinical [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":5785,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-5755","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Publications - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"Un aper\u00e7u de toutes les publications\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/fr\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - ASCERTAIN\" \/>\n<meta property=\"og:description\" content=\"Un aper\u00e7u de toutes les publications\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/fr\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-28T08:54:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/10\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47-1024x683.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/\",\"name\":\"Publications - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg\",\"datePublished\":\"2026-10-28T08:54:15+00:00\",\"dateModified\":\"2026-10-28T08:54:20+00:00\",\"description\":\"Un aper\u00e7u de toutes les publications\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg\",\"width\":2160,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/publications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/fr\\\/startseite\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - ASCERTAIN","description":"Un aper\u00e7u de toutes les publications","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/fr\/publications\/","og_locale":"fr_FR","og_type":"article","og_title":"Publications - ASCERTAIN","og_description":"Un aper\u00e7u de toutes les publications","og_url":"https:\/\/www.access2meds.eu\/fr\/publications\/","og_site_name":"ASCERTAIN","article_modified_time":"2026-10-28T08:54:20+00:00","og_image":[{"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/10\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47-1024x683.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/fr\/publications\/","url":"https:\/\/www.access2meds.eu\/fr\/publications\/","name":"Publications - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/fr\/publications\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/fr\/publications\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/10\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg","datePublished":"2026-10-28T08:54:15+00:00","dateModified":"2026-10-28T08:54:20+00:00","description":"Un aper\u00e7u de toutes les publications","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/fr\/publications\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/fr\/publications\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.access2meds.eu\/fr\/publications\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/10\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2026\/10\/Pierre-Yves-Jortay-Photography-Ascertain-2026-FINAL-WEB-FORMAT-47.jpg","width":2160,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/fr\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/fr\/startseite\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/5755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/comments?post=5755"}],"version-history":[{"count":2,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/5755\/revisions"}],"predecessor-version":[{"id":5772,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/pages\/5755\/revisions\/5772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/media\/5785"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/fr\/wp-json\/wp\/v2\/media?parent=5755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}